CN102836169A - Application of surfactant chemical ablation agent and preparation method in medicines for treating tumors - Google Patents
Application of surfactant chemical ablation agent and preparation method in medicines for treating tumors Download PDFInfo
- Publication number
- CN102836169A CN102836169A CN2011101743544A CN201110174354A CN102836169A CN 102836169 A CN102836169 A CN 102836169A CN 2011101743544 A CN2011101743544 A CN 2011101743544A CN 201110174354 A CN201110174354 A CN 201110174354A CN 102836169 A CN102836169 A CN 102836169A
- Authority
- CN
- China
- Prior art keywords
- surfactant
- chemical ablation
- lauryl alcohol
- alcohol polyoxyethylene
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a surfactant-lauryl alcohol polyoxyethylene chemical ablation agent and a preparation method thereof. The surfactant-lauryl alcohol polyoxyethylene chemical ablation agent disclosed by the invention can be used for performing chemical ablation treatment on tumors. A surfactant selected by the invention is of a hydrophilic variety of which the hydrophile lipophile balance (HLB) value is greater than 10. The greater the HLB value is, the stronger the hydrophilia of the surfactant is. The surfactant-lauryl alcohol polyoxyethylene chemical ablation agent is prepared mainly from a certain amount of surfactant and sterile injection water, for example, the surfactant and the sterile injection water are prepared into 1 percent of lauryl alcohol polyoxyethylene injection. The lauryl alcohol polyoxyethylene injection disclosed by the invention is colorless, tasteless, nontoxic and non-irritant and has no side effects. During an operating process that medical personnel ablates the tumors of a patient by using the surfactant-lauryl alcohol polyoxyethylene chemical ablation agent, the risk that the personnel is injured or equipment is damaged by the splashing of the injection does not exist.
Description
Preface
Nineteen eighty-three, Japanese scholar finds non-selective protein coagulation agent---ethanol can resemble and cell protein solidified the kill bacteria, thereby kills cancerous cell.After this physicians progressively are applied to clinically, through in the tumor body, injecting dehydrated alcohol, reach kill cancer cell, the purpose that makes tumor shrink or disappear, chemical ablation art that Here it is.
The chemical ablation art is applicable to that hepatocarcinoma, peripheral type carcinoma of lung, adrenal gland neoplasms, tumor of kidney, superficial lymph carry down to move etc. and can not performs the operation or refuse operator.
Do the chemical ablation agent with dehydrated alcohol, patient's allergic phenomena occurs.After getting into the nineties, physicians progressively adopt acetic acid, dilute hydrochloric acid, dilute sulfuric acid etc.But distinctive smell has hindered promotion and application with acetic acid, dilute hydrochloric acid, dilute sulfuric acid preparation and when the etching characteristic when using, acid volatilization.
Use the surfactant of hydrophile-lipophile balance value HLB (Hydrophile Lipophile Balance) greater than 10, the oriented adsorption function is strong, and hydrophilicity is good.Surfactant with certain content is processed aseptic parenteral solution, location under CT or B ultrasonic guiding., avirulence colourless, tasteless like " polyoxyethylene lauryl ether " injection, nothing irritates and the characteristics that have no side effect.The medical worker use the present invention as the operating process of patient's ablated tumor in, do not exist injection to spatter the risk of the person of hurting sb.'s feelings and damage equipment.Easy and simple to handle, patient's no pain, have no adverse reaction, the patient is prone to accept.
One, technical field
The present invention relates to make the Surfactant Chemistry of tumour ablation to melt agent, is the medicine of treatment tumor.
Two, summary of the invention
1, the chemical ablation agent of the present invention's selection is some specific surfactant, and the HLB VALUE OF SURFACTANTS HLB of selection (Hydrophile Lipophile Balance) is the hydrophilic kind greater than 10.Bigger its hydrophilic of HLB value is strong more, and the oriented adsorption merit is given strong more.Like the HLB value of polyoxyethylene lauryl ether, sodium lauryl sulphate, triethanolamine olein, potassium oleate, enuatrol, polysorbas20, polysorbate40, polysorbate60, Tween 80 etc. all greater than 10.
2, the present invention proposes " polyoxyethylene lauryl ether " injection especially, and its HLB value is 16.9.Hydrophilic is very strong.
3, find during the clinical use of " polyoxyethylene lauryl ether " injection; Patients with gastric cancer is with the other diseases of 1% " polyoxyethylene lauryl ether " injection for treating digestive system; Because of the needs prognosis is observed; Find simultaneously the phenomenon that the gastric cancer tumor can occur dwindling with 1% " polyoxyethylene lauryl ether " injection for treating digestive system disease.And generation many cases.
Confirm 1% " polyoxyethylene lauryl ether " injection to the melting of tumor in order to study, viewing test experimentizes.
The experimenter gets the live body stomach cancer cell, carries out isolated culture.Be placed in the culture dish respectively, and place constant temperature, constant humidity environment, inject culture fluid on time according to quantity.Under Electronic Speculum, observed the stomach cancer cell division, and guarantee that stomach cancer cell is in existing state in per 24 hours.
Be divided into two groups after seven days.First group of vessel still injects culture fluid on time according to quantity, and the monitoring stomach cancer cell is in existing state under Electronic Speculum.Second group of vessel also injects a certain amount of 1% " polyoxyethylene lauryl ether " injection except inject according to quantity the culture fluid on time, and the monitoring stomach cancer cell is in existing state under Electronic Speculum.
After three days, under Electronic Speculum, observe two groups of vessel stomach cancer cell survival and contrast.Stomach cancer cell proper splitting survival in first group of vessel.Withered death appears in the stomach cancer cell in second group of vessel.
Trace it to its cause and think, when " polyoxyethylene lauryl ether " with after tumor cell contacts, " polyoxyethylene lauryl ether " hydrophilic is very strong, has the oriented adsorption function.Its constantly draws the moisture content in tumor cell, and it is back withered that the tumor cell dehydration can't be grown, and then reach the ablated tumor cell.
Three, implementation method
" " polyoxyethylene lauryl ether " injection " is that a certain amount of " polyoxyethylene lauryl ether " is formulated with sterile water for injection.The content of " polyoxyethylene lauryl ether " is 0.5% to 50%.
Except that " polyoxyethylene lauryl ether ", this description two, 1, in other HLB also can be mixed with the injection of certain content with sterile water for injection greater than 10 hydrophilic surfactant active, the content of these surfactants is 0.5% to 50%.
Claims (2)
- A kind of Surfactant Chemistry that is used for tumour ablation melts agent.It is characterized in that:1. the chemical ablation agent of selecting is a kind of surfactant, and its hydrophile-lipophile balance value HLB (Hydrophile Lipophile Balance) is the hydrophilic kind greater than 10.The following kind of surfactant that claim is selected:Polyoxyethylene lauryl ether, sodium lauryl sulphate, triethanolamine olein, potassium oleate, enuatrol, polysorbas20, polysorbate40, polysorbate60, Tween 80 etc.
- 2. the claim surfactant is used as the content of chemical ablation agent:Surfactant is used as the content from 0.5% to 50% of chemical ablation agent, and prepares with sterile water for injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101743544A CN102836169A (en) | 2011-06-24 | 2011-06-24 | Application of surfactant chemical ablation agent and preparation method in medicines for treating tumors |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101743544A CN102836169A (en) | 2011-06-24 | 2011-06-24 | Application of surfactant chemical ablation agent and preparation method in medicines for treating tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102836169A true CN102836169A (en) | 2012-12-26 |
Family
ID=47364072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011101743544A Pending CN102836169A (en) | 2011-06-24 | 2011-06-24 | Application of surfactant chemical ablation agent and preparation method in medicines for treating tumors |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102836169A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1739550A (en) * | 2005-09-16 | 2006-03-01 | 陕西天宇制药有限公司 | Polycinnamic alcohol injection and its prepn |
-
2011
- 2011-06-24 CN CN2011101743544A patent/CN102836169A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1739550A (en) * | 2005-09-16 | 2006-03-01 | 陕西天宇制药有限公司 | Polycinnamic alcohol injection and its prepn |
Non-Patent Citations (2)
| Title |
|---|
| 王永光: "聚桂醇：新型的微创硬化治疗技术", 《微创医学》, vol. 6, no. 1, 25 February 2011 (2011-02-25) * |
| 陈虹等: "AEO对肿瘤细胞抑制作用的初步研究", 《山东医药》, vol. 34, no. 12, 31 December 1994 (1994-12-31) * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102258503B (en) | Topical co-enzyme Q 10 formulations and its application method | |
| CN107666902A (en) | Local medicine composition | |
| CN104523473B (en) | A kind of anti-acne microemulsion system and preparation method thereof | |
| CN110139662A (en) | The antiphlogistic use of peptide | |
| CN105477017A (en) | Mixed stem cell preparation for treating diabetic foot and preparation method of mixed stem cell preparation | |
| CN103948575A (en) | Application of cinnamyl aldehyde in preparing medicament for promoting angiogenesis | |
| CN105251011B (en) | A kind of spray-filming agent and preparation method thereof for superficial burns | |
| CN102688507A (en) | Disinfection and sterilization couplant and its preparation method | |
| Follador et al. | Cutaneous protothecosis: report of the second Brazilian case | |
| JP2009269904A (en) | Herbal medicinal composition for curing external wound and bedsore and method of manufacturing medicine from the composition | |
| CN108096315A (en) | A kind of preparation method and preparation of a new generation's anti-acne compound medicine | |
| Hofmannova et al. | Unusual cases of Taenia crassiceps cysticercosis in naturally infected animals in the Czech Republic. | |
| CN105963243B (en) | A kind of borneol cinnamomum camphora essential oil sustained release emulsifiable paste and preparation method thereof for treating acne vulgaris | |
| CN102836169A (en) | Application of surfactant chemical ablation agent and preparation method in medicines for treating tumors | |
| Dadashpour Davachi | Vasectomy in mouse model using electrosurgery machine | |
| CN107427555A (en) | Healthy reproduction and suppress the composition and method of hyperketonemia using IL 8 to increase the output of milk and improve in mammal | |
| Henning et al. | Glomuvenous malformations | |
| CN109260426B (en) | External traditional Chinese medicine for eliminating mass, eliminating stagnation and relieving pain and preparation method and application thereof | |
| CN104225583B (en) | A kind of compositions repaired for skin injury | |
| CN105101969B (en) | Antivirotic composition comprising boric acid, citric acid and zinc | |
| Boettcher et al. | A comprehensive protocol for laparotomy in swine to facilitate ultrasound-guided injection into the fetal intraperitoneal space | |
| Whitfield | A handbook of skin diseases and their treatment | |
| Sławińska et al. | An unexpected cause of an itchy tattoo revealed in videodermoscopic examination | |
| Grillo et al. | Neutrophilic eccrine hidroadenitis with atypical findings | |
| Papadopoulos et al. | Administration of moxidectin for treatment of sarcoptic mange in a flock of sheep |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20121226 |